XLRN-517 (anti-C-KIT)

An Anti-C-KIT mAb With A Lead Indication for Chronic Urticaria (CU)

XLRN-517 is a pre-IND anti-C-KIT, a known mechanism with external proof of concept in Chronic Urticaria (CU), being studied as a treatment option in CU, a potentially greater than $2.5 billion estimated market opportunity. Mast cells (MCs) are derived from bone marrow and develop in response to stem cell factor (SCF), the natural ligand of c-KIT. As mast cell activation is implicated in numerous diseases—including anaphylaxis, allergic rhinitis, asthma, atopic dermatitis, food allergies, and others—there are multiple additional indications that could also be targeted in the future.
An Anti-C-KIT mAb With A Lead Indication for Chronic Urticaria (CU)
Indications

Chronic Urticaria

Chronic urticaria (CU) is caused by MC degranulation following activation by IgE. It can be spontaneous (idiopathic) or triggered by physical stimuli (e.g., heat). Symptoms include urticaria (hives), itching, erythema, angioedema, headache, fatigue, and pain. About 2 million patients in the US suffer from urticaria at any given time.

*Izokibep is not yet approved for use in any indication.
News Center

The Latest Company
Announcements and Resources